Variable effects of alpha v suppression on VEGFR-2 expression in endothelial cells of different vascular beds

Summary

Integrins αvβ3 and αvβ5 have been long considered as proangiogenic receptors, yet genetic ablation studies demonstrated enhanced angiogenesis in mice lacking αvβ3 and αvβ5 integrins, which was attributed to increased expression of vascular endothelial growth factor receptor-2 (VEGFR-2). In this study, we determined the effect of αvβ3 and αvβ5 suppression in endothelial cells (EC) on vascular endothelial growth factor (VEGF) and VEGFR-2 expression. αv was suppressed by shRNA in HUVEC (venous endothelial cells) and HMVEC (microvascular endothelial cells).VEGFR-2 was significantly upregulated by αv suppression in HUVEC and downregulated in HMVEC at both mRNA and protein levels,as assessed by real-time PCR and flow cytometry,respectively.HMVEC displayed completely abolished Sp1 binding to the VEGFR-2 promoter, and HUVEC exhibited enhanced binding to the –170 E- Box element in the VEGFR-2 promoter, assessed by electrophoretic mobility shift assay. Realtime PCR also revealed opposite effects on the expression of 5 additional important genes involved in angiogenesis in the two cell types.VEGF mRNA expression was enhanced in HUVEC and reduced in HMVEC; however, these alterations were not statistically significant.VEGF-induced proliferation was upregulated in HUVEC and reduced in HMVEC following αv suppression. No tube formation on Matrigel was observed in αv suppressed cells, regardless of their origin.These results indicate that suppression of αv integrins can either augment or inhibit VEGFR-2 levels and VEGF-induced proliferation in EC from different vascular beds. Hence, therapeutic antiangiogenic intervention by siRN-Amediated suppression of αv integrins should take into account variable and potentially hazardous responses in different vascular beds.

Keywords

Angiogenesis - αvβ3 and αvβ5 integrins - αvβ3 and αvβ5 inhibitors - αv suppression - siRNA

• References

• 1 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 09: 653-660.
• 2 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 09: 669-676.
• 3 Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21.
• 4 Brooks PC, Montgomery AM, Rosenfeld M. et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
• 5 Brooks PC, Stromblad S, Klemke R. et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
• 6 Fu Y, Ponce ML, Thill M. et al. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci 2007; 48: 5184-5190.
• 7 Eskens FA, Dumez H, Hoekstra R. et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39: 917-926.
• 8 Gutheil JC, Campbell TN, Pierce PR. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 06: 3056-3061.
• 9 Reardon DA, Nabors LB, Stupp R. et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17: 1225-1235.
• 10 Maubant S, Saint-Dizier D, Boutillon M. et al. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006; 108: 3035-3044.
• 11 Reynolds LE, Wyder L, Lively JC. et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 08: 27-34.
• 12 Reynolds AR, Reynolds LE, Nagel TE. et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 2004; 64: 8643-8650.
• 13 Bader BL, Rayburn H, Crowley D. et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95: 507-519.
• 14 McCarty JH, Monahan-Earley RA, Brown LF. et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 2002; 22: 7667-7677.
• 15 Dejong V, Degeorges A, Filleur S. et al. The Wilms’ tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene 1999; 18: 3143-3151.
• 16 Hata Y, Duh E, Zhang K. et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 1998; 273: 19294-19303.
• 17 Jackson TA, Taylor HE, Sharma D. et al. Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFIIIRD1. J Biol Chem 2005; 280: 29856-29863.
• 18 Sheppard D. Endothelial integrins and angiogenesis: not so simple anymore. J Clin Invest 2002; 110: 913-914.
• 19 Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131-144.
• 20 Wilkinson-Berka JL, Jones D, Taylor G. et al. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2006; 47: 1600-1605.
• 21 Taverna D, Moher H, Crowley D. et al. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A 2004; 101: 763-768.
• 22 Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 08: 918-921.
• 23 Reynolds AR, Hart IR, Watson AR. et al. .Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
• 24 Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 2000; 275: 39867-39873.
• 25 Soldi R, Mitola S, Strasly M. et al. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999; 18: 882-892.
• 26 Chi JT, Chang HY, Haraldsen G. et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003; 100: 10623-10628.
• 27 McCarty JH, Lacy-Hulbert A, Charest A. et al. Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development 2005; 132: 165-176.
• 28 Graef T, Steidl U, Nedbal W. et al. Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis. Angiogenesis 2005; 08: 361-372.
• 29 Salomon O, Steinberg DM, Koren-Morag N. et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.